GLP-1 Collective

Policy Tracker · Patient Lens · September 19, 2026

Seven GLP-1 trials are testing what these drugs can do beyond weight

From liver disease to asthma to muscle loss during treatment, the next wave of approvals hinges on results still years away.

Key details

  • Novo Nordisk's suit against Dr. Reddy's may affect generic access timing.
  • Coffin v. Novo Nordisk, over Ozempic or Wegovy, remains pending with details undisclosed.
  • Cole v. Eli Lilly & Company is a pending lawsuit tied to Eli Lilly's GLP-1 drugs.
  • Parker v. Novo Nordisk A/S is pending and may lead to new drug label warnings.

7 developments affecting GLP-1 access were tracked on Friday, September 18, 2026, across 1 category. Each entry links to the full record.

## Research and trials

**[New drug tested alongside semaglutide for more weight loss](/fda/clinical-trial-nct07220629)**. A small early study is testing a new drug added on top of semaglutide to see if it helps people lose more weight.

**[Amgen's new obesity drug maritide in final FDA testing stage](/fda/clinical-trial-nct06858839)**. Amgen is running a large Phase 3 trial for maritide, a new obesity drug, but it is not available to patients yet.

**[New GLP-1 drug survodutide tested for scarred livers](/fda/clinical-trial-nct06632444)**. A large Phase 3 trial is now recruiting people with obesity and MASH liver disease to test a new drug called survodutide.

**[Survodutide heart safety trial finished, results coming mid-2026](/fda/clinical-trial-nct06077864)**. Survodutide is still being tested and is not available to the public yet, results are expected by mid-2026.

**[Semaglutide tested for asthma control in people with obesity](/fda/clinical-trial-nct05254314)**. A clinical trial is testing whether semaglutide (Wegovy/Ozempic) can improve asthma control in people with obesity.

**[Survodutide Phase 3 trial: what's next for this GLP-1 competitor](/fda/clinical-trial-nct07754461)**. Survodutide is still in clinical trials and is not yet approved or available as a treatment.

**[Study to test strength training and tirzepatide muscle loss](/fda/clinical-trial-nct07777575)**. A new study will test whether strength training prevents muscle loss when taking tirzepatide for weight loss.

By Amanda Bonello

Originally published by Patient Lens on GLP-1 Laws, operated by GLP-1 Studio LLC — a for-profit company founded by the Collective's Executive Director. Republished here in full, with permission, at no cost. The Collective pays nothing for it and receives no payment for publishing it. How this works.